<DOC>
	<DOCNO>NCT00676910</DOCNO>
	<brief_summary>The purpose study assess safety JNJ-26854165 ( new drug development cancer ) patient advanced refractory solid tumor maximum dose tolerated patient .</brief_summary>
	<brief_title>A Research Study JNJ-26854165 Determine Safety Dose Patients With Advanced Stage Refractory Solid Tumors .</brief_title>
	<detailed_description>JNJ-26854165 new drug development belongs class drug act specific protein present cell . It may stop cancer cell grow kill cancer cell . In study , safety ( effect body ) JNJ-26854165 patient advanced refractory solid tumor examine . The effect ( ) JNJ-26854165 disease assess throughout study . The maximum dose tolerate patient determine . The dose JNJ 26854165 start low increase study . The drug take mouth every day 21-day cycle . The dose patient receives assign enrollment . Patients enroll late time may receive high dose . If patient severe side effect certain dose level , next group 3 6 patient get high dose . The dose increase patient severe side effect . The dose decrease 3 6 patient receive high amount drug non-severe side effect observe . The amount JNJ 26854165 blood measure effect JNJ 26854165 disease also monitor . The effect food absorption , break elimination drug study patient . At dose level , possible interaction JNJ 26854165 medication frequently use cancer patient examine patient dose level ask take single dose three additional drug ( dextromethorphan hydrobromide ( 30mg ) , tolbutamide ( 250mg ) , midazolam ( 5mg ) `` cocktail '' ) 2 study day , supply study doctor . Patients screen eligibility 4 week study drug administer . During Cycle 1 patient observed inpatient least 12 hour administration drug 3 4 day require visit study site 2 additional day . One additional visit require patient food effect interaction medication examine . During Cycle 2 , patient require visit study center 2 day . During cycle Cycle 2 , patient require visit study center 1 day . Fourteen day last dose JNJ-26854165 , patient invite follow-up visit include test safety effect drug disease . The propose start dose JNJ-26854165 4 mg/day single oral dose . JNJ26854165 provide glass vial tear-off cap place child resistant pouch drug may take home . Patients take JNJ-26854165 day study . Treatment may continue long benefit unacceptable side effect assess study doctor .</detailed_description>
	<criteria>Confirmed solid malignancy , advance , incurable stage responsive available therapy performance status ( base Eastern Cooperative Oncology Group assessment ) &lt; = 2 life expectancy &gt; 3 month must consent skin biopsy must meet protocoldefined criterion lab assessment heart function . Known central nervous system metastasis chemotherapy , radiotherapy , immunotherapy use investigational agent within 2 week dose treatment within last 6 month expect require treatment amiodarone derivates study participation currently treat and/or expect require treatment warfarin/coumarine derivates study participation history uncontrolled heart disease uncontrolled arterial hypertension eye abnormality screen examination &gt; 70 % stenosis lumen Carotid duplex assessment screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Malignancies</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Incurable Solid Cancers</keyword>
</DOC>